Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical has acquired rights to patents and intellectual property relating to the use of electroporation technology for use in the therapeutic delivery of DNA, from the small French biotechnology company, Sphergen.
Subscribe to our email newsletter
The rights Inovio has licensed include two patents with broad claims regarding electroporation of nucleic acids in muscle and tumor tissue. The license also includes grants of rights to know how, future improvements, and provisions for exclusivity in applications to human medicine.
In 1993 Inovio received a patent for electroporation using needle electrodes for gene and drug delivery in human applications including DNA vaccination in muscle and other tissues.
Inovio has since continued to expand its position by acquiring additional patents covering electroporation-assisted delivery of genes in muscle tissue, which is now being studied as a primary target tissue for delivering DNA-based therapies.
“Inovio's patent portfolio is a significant asset to facilitate the commercialization of DNA therapeutics delivered using electroporation, particularly in muscle tissue. Such therapeutics include DNA vaccines, which are increasingly recognized as having tremendous potential to treat or prevent a range of conditions such as infectious diseases and cancers,” said Dr Avtar Dhillon, CEO of Inovio Biomedical.